Endothelial cell antigens (ECA)

Endothelial cell antigens (ECA) represent a heterogeneous collection of proteins, glycoproteins, and glycolipids expressed on the surface of endothelial cells, which form the inner lining of blood vessels. These antigens are vital for maintaining vascular integrity and regulating processes such as angiogenesis, leukocyte recruitment, and blood pressure through signaling and adhesion mechanisms (Safety of targeting tumor endothelial cell antigens, PMC4847341; NHLBI workshop report, PMID 15142844). In oncology, specific ECAs like Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), Endoglin (CD105), and Tumor Endothelial Marker 1 (TEM1) are frequently upregulated in the tumor neovasculature, serving as targets for anti-angiogenic drugs and therapeutic vaccines like ValloVax (Induction and characterization of anti-tumor endothelium immunity..., PMID 28445150). Beyond cancer, ECAs are significant in immunology; they are the primary targets of anti-endothelial cell antibodies (AECA) in various autoimmune vasculitides and are critical mediators of antibody-mediated rejection in organ transplantation (Vascular Endothelium as a Target of Immune Response in Renal Transplant Rejection, PMID 29616037). Therapeutic modulation of these antigens aims to either inhibit pathological vessel growth or suppress the immune-mediated destruction of the vascular endothelium, though such interventions carry risks of systemic vascular toxicity, including hypertension and impaired wound healing (Safety of targeting tumor endothelial cell antigens, PMC4847341). Because the term refers to a broad category of molecules rather than a single specific protein, it is often considered a collective target in the context of polyvalent immunotherapy.

Other names

Anti-endothelial cell antibody targetsVascular antigensTumor endothelial antigensEndothelial surface proteinsEndothelial cell-restricted antigens

Inhibition of angiogenesis by blocking growth factor receptors, induction of antibody-dependent cellular cytotoxicity (ADCC) against tumor vasculature, and targeted delivery of therapeutic agents to the endothelial surface.